Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia - PubMed (original) (raw)
. 2002 Nov;87(11):4957-60.
doi: 10.1210/jc.2002-021105.
Affiliations
- PMID: 12414858
- DOI: 10.1210/jc.2002-021105
Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia
Yuji Yamazaki et al. J Clin Endocrinol Metab. 2002 Nov.
Abstract
Hypophosphatemic rickets/osteomalacia with inappropriately low serum 1,25-dihidroxyvitamin D level is commonly observed in X-linked hypophosphatemic rickets/osteomalacia, autosomal dominant hypophosphatemic rickets/osteomalacia and tumor-induced osteomalacia. Although the involvement of a newly identified factor, FGF-23, in the pathogenesis of ADHR and TIO has been suggested, clinical evidence indicating the role of FGF-23 has been lacking. We have previously shown that FGF-23 is cleaved between Arg(179) and Ser(180), and this processing abolished biological activity of FGF-23 to induce hypophosphatemia. Therefore, sandwich ELISA for biologically active intact human FGF-23 was developed using two kinds of monoclonal antibodies that requires the simultaneous presence of both the N-terminal and C-terminal portion of FGF-23. The serum levels of FGF-23 in healthy adults were measurable and ranged from 8.2 to 54.3 ng/L. In contrast, those in a patient with TIO were over 200 ng/L. After the resection of the responsible tumor, the elevated FGF-23 level returned to normal level within 1 h. The increase of serum concentrations of 1,25-dihidroxyvitamin D and phosphate, and the decrease of serum 24,25-dihydroxyvitamin D followed the change of FGF-23. In addition, the elevated serum FGF-23 levels were demonstrated in most patients with XLH. It is likely that increased serum levels of FGF-23 contributes to the development of hypophosphatemia not only in TIO but also in XLH.
Similar articles
- Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H. Jonsson KB, et al. N Engl J Med. 2003 Apr 24;348(17):1656-63. doi: 10.1056/NEJMoa020881. N Engl J Med. 2003. PMID: 12711740 - Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia.
Xia WB, Jiang Y, Li M, Xing XP, Wang O, Hu YY, Zhang HB, Liu HC, Meng XW, Zhou XY. Xia WB, et al. Chin Med J (Engl). 2010 May 5;123(9):1158-62. Chin Med J (Engl). 2010. PMID: 20529556 - Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin.
Fukumoto S, Yamashita T. Fukumoto S, et al. Curr Opin Nephrol Hypertens. 2002 Jul;11(4):385-9. doi: 10.1097/00041552-200207000-00003. Curr Opin Nephrol Hypertens. 2002. PMID: 12105387 Review. - Emerging role of a phosphatonin in mineral homeostasis and its derangements.
Bielesz B. Bielesz B. Eur J Clin Invest. 2006 Aug;36 Suppl 2:34-42. doi: 10.1111/j.1365-2362.2006.01659.x. Eur J Clin Invest. 2006. PMID: 16884396 Review.
Cited by
- Exploring endocrine FGFs - structures, functions and biomedical applications.
Phan P, Ternier G, Edirisinghe O, Kumar TKS. Phan P, et al. Int J Biochem Mol Biol. 2024 Aug 25;15(4):68-99. doi: 10.62347/PALK2137. eCollection 2024. Int J Biochem Mol Biol. 2024. PMID: 39309613 Free PMC article. Review. - Chronic Kidney Disease and Growth Failure in Children.
Todisco T, Ubertini GM, Bizzarri C, Loche S, Cappa M. Todisco T, et al. Children (Basel). 2024 Jul 1;11(7):808. doi: 10.3390/children11070808. Children (Basel). 2024. PMID: 39062256 Free PMC article. Review. - FGF23 directly inhibits osteoprogenitor differentiation in Dmp1-knockout mice.
Courbon G, Kentrup D, Thomas JJ, Wang X, Tsai HH, Spindler J, Von Drasek J, Ndjonko LM, Martinez-Calle M, Lynch S, Hivert L, Wang X, Chang W, Feng JQ, David V, Martin A. Courbon G, et al. JCI Insight. 2023 Dec 22;8(24):e156850. doi: 10.1172/jci.insight.156850. JCI Insight. 2023. PMID: 37943605 Free PMC article. - Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study.
Lapsina S, Nagler N, Müller SF, Holtdirk A, Kottmann T, Müller E, von Luckner J, Schäfer I. Lapsina S, et al. Animals (Basel). 2023 Jun 2;13(11):1853. doi: 10.3390/ani13111853. Animals (Basel). 2023. PMID: 37889764 Free PMC article. - FGF23 AND ALTERED MINERAL HOMEOSTASIS IN KIDNEY DISEASE AND FOLLOWING INTRAVENOUS IRON.
Wolf M. Wolf M. Trans Am Clin Climatol Assoc. 2023;133:262-273. Trans Am Clin Climatol Assoc. 2023. PMID: 37701608 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous